Literature DB >> 11865445

Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts.

Stephen Parmley1, Teri Slifer, Fausto Araujo.   

Abstract

A portion of the major Toxoplasma gondii tissue cyst antigen (MAG1) was expressed in bacteria as a fusion to glutathione S-transferase (GST) and the purified fusion protein (rMAG1) was used to immunize mice in an attempt to induce protective immunity against challenge with live cysts from the T. gondii ME49 strain. Sixty percent of mice immunized with rMAG1 and challenged with 500 cysts of the T. gondii ME49 strain survived, while only 20% of mice immunized with GST alone survived, suggesting a protective effect specific to the MAG1 portion of the recombinant protein. In a model of chronic infection with ME49 cysts, rMAG1-immunized mice had significantly fewer cerebral cysts and reduced inflammation in the brain compared with mice immunized with GST alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865445     DOI: 10.1086/338464

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Use of MAG1 recombinant antigen for diagnosis of Toxoplasma gondii infection in humans.

Authors:  Lucyna Holec; Elzbieta Hiszczyńska-Sawicka; Artur Gasior; Anna Brillowska-Dabrowska; Józef Kur
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

2.  Comparative study of protective activities of Neospora caninum bradyzoite antigens, NcBAG1, NcBSR4, NcMAG1, and NcSAG4, in a mouse model of acute parasitic infection.

Authors:  Masaki Uchida; Kotomi Nagashima; Yui Akatsuka; Takashi Murakami; Akira Ito; Soichi Imai; Kazunori Ike
Journal:  Parasitol Res       Date:  2012-11-15       Impact factor: 2.289

3.  Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.

Authors:  Valentina Martin; Alicia Supanitsky; Pablo C Echeverria; Silvana Litwin; Tamara Tanos; Adolfo R De Roodt; Eduardo A Guarnera; Sergio O Angel
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 4.  A latent ability to persist: differentiation in Toxoplasma gondii.

Authors:  Victoria Jeffers; Zoi Tampaki; Kami Kim; William J Sullivan
Journal:  Cell Mol Life Sci       Date:  2018-03-30       Impact factor: 9.261

5.  Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.

Authors:  Jason P Gigley; Barbara A Fox; David J Bzik
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

6.  Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice.

Authors:  Angelika Wagner; Irma Schabussova; Bärbel Ruttkowski; Roman Peschke; Józef Kur; Michael Kundi; Anja Joachim; Ursula Wiedermann
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

7.  Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice.

Authors:  Hai-Long Wang; Tie-E Zhang; Li-Tian Yin; Min Pang; Li Guan; Hong-Li Liu; Jian-Hong Zhang; Xiao-Li Meng; Ji-Zhong Bai; Guo-Ping Zheng; Guo-Rong Yin
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

8.  Discovery of new Toxoplasma gondii antigenic proteins using a high throughput protein microarray approach screening sera of murine model infected orally with oocysts and tissue cysts.

Authors:  Mert Döşkaya; Li Liang; Aarti Jain; Hüseyin Can; Sultan Gülçe İz; Philip Louis Felgner; Aysu Değirmenci Döşkaya; David Huw Davies; Adnan Yüksel Gürüz
Journal:  Parasit Vectors       Date:  2018-07-04       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.